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Abstract Vasoactive intestinal polypeptide (VIP) exhibits
effects on cell proliferation. Here, VIP, as well as the related
peptide, pituitary adenylate cyclase activating peptide (PACAP),
promoted human keratinocyte division. Stearyl-Nle17-VIP
(SNV) was identified as a superior mitogen for the keratinocytic
cell line, HaCaT, both in potency (fM^nM concentrations) and
efficacy. Reverse transcription-polymerase chain reaction de-
tected in keratinocytes only PACAP mRNA and the relevant
type 1 (VPAC1R) and type 2 (VPAC2R) receptors, while VIP
and the third receptor (PAC1) transcripts were absent. Upon
serum deprivation of HaCaT, the VPAC1R mRNA was
apparently increased, while the VPAC2R transcript remained
constant. Incubation of HaCaT with VIP or SNV increased
nitric oxide and cGMP formation. In contrast to VIP, SNV did
not augment cAMP. Thus, the paracrine VIP, and autocrine
PACAP, related pathways leading to keratinocyte proliferation
may involve VPAC1R/VPAC2R and nitric oxide/cGMP pro-
duction. ß 2000 Federation of European Biochemical Socie-
ties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Previous work has already identi¢ed vasoactive intestinal
peptide (VIP) [1,2] as a modulator of growth, survival and
di¡erentiation in many cell systems, including the brain, the
gastro-intestinal tract, lung and immune system, of both pri-
mary origin and cancerous one [1]. Pituitary adenylate cyclase
activating peptide (PACAP) is a 27 or 38 amino acid peptide,
originally isolated from ovine hypothalamus by Arimura’s
group [3], which reveals 68% homology to VIP. VIP and PA-
CAP receptors belong to the seven transmembrane domain
superfamily of receptors, which share many properties, and
are named PACAP/VIP receptors (PAC/VPAC). Three main
receptor molecules have been cloned: PAC1, VPAC1 and
VPAC2 [4]. The three receptor subtypes display a binding
potency as follows: PAC1R, PACAP38 = PACAP27FVIP;
VPAC1R, VIP = PACAP279PACAP38; and VPAC2R,
VIP = PACAP38 = PACAP27. In situ hybridization experi-
ments indicated the following. (1) The major site of VPAC1R
is the lung, with some expression in other peripheral tissues,
such as liver and T lymphocytes. (2) The VPAC2R is predom-
inantly distributed in organs other than the lung, including the
pancreas, skeletal muscle, heart, kidney, adipose tissue, testis
and stomach. (3) The PAC1R mRNA was found predomi-
nantly in the brain and in the adrenal medulla [1]. VPAC
are G-protein-coupled receptors, which activate adenylate cy-
clase- and phospholipase C-dependent signaling pathways. As
in the rat [5], molecular cloning of PAC1 identi¢ed several
splice variants of this receptor in humans [6].
VIP e¡ects have been documented for skin cells [7^9]. The
major cell type in the epidermis (the outermost skin layer) is
the keratinocyte [10]. Normal human skin contains a variety
of neuropeptides [11]. Evidence pertaining to direct e¡ects of
VIP on keratinocytes, include the original report by Haeger-
strand [7] and later by Pincelli [8] that have demonstrated a
mitogenic e¡ect exerted by VIP on cultured human keratino-
cytes when co-incubated with epidermal growth factor (EGF).
Rabier et al. [9] reported a more extensive e¡ect of VIP on
cultured human keratinocytes in the absence of EGF, using
serum-free conditions. Haegerstrand has further demonstrated
parallel increases in cAMP levels in response to VIP, associ-
ating this second messenger with the proliferative e¡ect of the
peptide [7].
The focus of the present study was the evaluation of the
nature of interactions between VIP and its related peptide,
PACAP27 with keratinocytes. More speci¢cally, these include
the following. (1) Examination of VIP and PACAP27 induced
proliferation of keratinocytes. (2) Examination of receptors’
expression involved in the proliferative e¡ect and the possible
in£uence of culture conditions on this expression. (3) Charac-
terization of VIP and PACAP27 for autocrine or paracrine
activity. (4) Examination of the second messengers involved
down-stream to receptor activation.
Furthermore, we developed a lipophilic super active analog
of VIP, stearyl-Nle17-VIP (SNV) [12], that contains two chem-
ical modi¢cations in VIP: the addition of an N-terminal long
chain aliphatic acid and the substitution of the Met in posi-
tion 17 with Nle. These changes confer stability, longer half-
life and increased bioavailability. This analog exhibited both a
100-fold potency as compared to VIP (maximal e¡ect mani-
fested at 1 pM) and speci¢city for a VIP receptor in neuronal
survival and neuroprotection against the L-amyloid peptide
fragment (the Alzheimer’s disease neurotoxin) [13,14]. Thus,
the ¢fth goal of the current study was the evaluation of the
VIP lipophilic analog, SNV, on keratinocyte proliferation,
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with emphasis on relevance to possible therapeutic applica-
tion.
2. Materials and methods
2.1. Solid phase peptide synthesis
Peptides were prepared by solid phase peptide synthesis using the
Fmoc chemistry as described elsewhere [12,15]. VIP (HSDAVFTD-
NYTRLRKQMAVKKYLNSILN-NH2), PACAP27 (HSDGIFTD-
SYSRYRKQMAVKKYLAAVL-NH2) and SNV (stearyl-HSDA-
VFTDNYTRLRKQ-Nle-AVKKYLNSILN-NH2) were puri¢ed by
reverse phase high performance liquid chromatography as before
(see adjoining manuscript).
2.2. Cell cultures
2.2.1. Neonatal keratinocytes. Primary neonatal human epidermal
keratinocytes (NHEK) were purchased from Clonetics (CA, USA) in
their cryopreserved form and cultivated in keratinocyte serum-free
medium (K-SFM, Gibco-BRL, Gaithersburg, MD, USA) supple-
mented with 25 Wg/ml bovine pituitary extract (BPE) and 0.1 ng/ml
human recombinant EGF. Keratinocytes used for experimentation
were tertiary (3‡) or quaternary (4‡), i.e. they have undergone 2 or
3 trypsinizations and sub-culturing steps, respectively, prior to assay-
ing their proliferation.
2.2.2. HaCaT. Human HaCaT keratinocytes were a kind gift
from Professor Fusenig [16]. The cells were routinely propagated in
minimal Eagle’s essential medium (MEM) supplemented with 1% Pen-
Strep-Nystatin, 2 mM L-Gln and 10% fetal calf serum (FCS, Biolog-
ical Industries, Beit Haemek, Israel) under humidi¢ed atmosphere
with 10% CO2 at 37‡C.
2.3. [3H]Thymidine incorporation assay
2.3.1. Neonatal keratinocytes. Human keratinocytes were assayed
essentially as described by Rabier [9]. Brie£y, 150 000 cells were seeded
into 35 mm dishes (Nunc, Roskilde, Denmark) in K-SFM and grown
until 50% con£uence. Medium was replaced every other day. At 50%
con£uence, the medium was changed to K-SFM without EGF and
BPE (basal medium), in order to achieve a quiescent state. Following
48 h, the medium was replaced by fresh basal medium supplemented
with VIP/PACAP27 at the indicated concentrations for an additional
22^24 h. The e¡ects of the peptides were monitored by [3H]thymidine
incorporation (4 WCi/dish) during the last 4 h of incubation. Cells
were dissolved by 0.25 N NaOH and ¢ltered through GF/C glass
¢lters. Radioactivity was measured by L-counter with Packard’s
Opti-Fluor scintillation liquid.
2.3.2. HaCaT. The HaCaT cell growth protocol consisted of seed-
ing cells, at a density of 4U105 per 35 mm dish (Corning, MA, USA),
in 5% FCS-supplemented MEM, as above. On the following day, cells
were starved by changing the medium to MEM supplemented with
0.1% bovine serum albumin (BSA) for a 48 h period, after which the
peptides were added, in fresh serum-free medium, at the speci¢ed
concentrations and incubation proceeded for 22^24 h period. The
e¡ects of the peptides were monitored by [3H]thymidine incorporation
(4 WCi/dish) during the last 4 h of incubation. Cells were processed as
neonatal keratinocytes for radioactive counts.
2.4. Measurements of intracellular cAMP/cGMP accumulation
HaCaT cells were plated as for the proliferation protocol. After 24
h, the medium was changed to serum-free medium for an additional
48 h. On the fourth day, the medium was changed to fresh MEM
(without supplements). VIP and SNV were added for a stimulation
period of 15 min. Control cultures received saline. Cultures were then
washed three times with cold phosphate-bu¡ered saline and the cyclic
nucleotides were extracted by a 30 min incubation period at 4‡C in
80% ethanol, followed by mechanical removal of the cells. The result-
ing suspension was pelleted by centrifugation at 2000Ug for 15 min at
4‡C. The supernatants were transferred to fresh tubes and dried by
Eppendorf concentrator 5301 (Eppendorf, Hamburg, Germany). Sam-
ples were then assayed by a cAMP or cGMP enzyme-immunoassay
(EIA) system kit (RPN 225 or 226, respectively, Amersham, UK)
according to the manufacturer’s instructions.
2.5. NO determination
Quanti¢cation of NO secretion was based on the appearance of its
metabolite, NO32 , in the culture media, following the exposure of cells
to VIP, using 0.1% BSA-supplemented phenol-red-free Dulbecco’s
modi¢ed MEM. Following 24 h incubation, a 100 Wl aliquot of the
culture media was mixed with 50 Wl of Griess reagent, prepared by
mixing a 1:1 ratio of 0.1% N-(1-naphthyl)-ethylenediamine (Sigma, St.
Louis, MO, USA) and 1% sulfanilamide (Sigma) in 5% phosphoric
acid [17]. After 10 min incubation at room temperature, the absor-
bance was determined in a microplate reader at 550 nm. The nitrite
concentration was determined with sodium nitrite in medium as a
standard and the medium not exposed to cells was used as a blank.
2.6. RNA extraction
Total RNA from cultured cells (HaCaT or 3‡ NHEK) was ex-
tracted by RNAzol B reagent (Biotecx, TX, USA) according to the
manufacturer’s protocol. Brie£y, cells grown on 100 mm Petri dishes,
either in 10% FCS-supplemented MEM or following the starvation
protocol, were dissolved in 5 ml RNAzol B reagent.
2.7. Reverse transcription-polymerase chain reaction (RT-PCR)
Complementary DNA was ¢rst obtained by reverse transcription of
2 Wg total RNA with M-MLV reverse transcriptase (200 U, Gibco-
BRL) using random hexamers as primers (1 h at 37‡C, 5 min at 95‡C).
This reaction was followed by 30^35 PCR ampli¢cation cycles using
Red Hot DNA polymerase (5 U, advanced Biotechnologies) (1 min at
94‡C, primer annealing at 60‡C for 1 min, extension at 72‡C for 1 min)
using MJ Research thermal cycler. In order to control the RNA
quantity of di¡erent samples, 2 Wl samples of cDNA were ampli¢ed
in parallel to the test primers with speci¢c primers for the human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers specif-
ic for VIP, PACAP, VPAC1R, VPAC2R, PAC1R, as well as GAPDH,
are speci¢ed in Table 1 (nucleotide position refers to the correspond-
ing mRNA sequence).
PCR products were electrophoresed on a 2% Nusieve GTG agarose
gel (FMC Bioproducts, ME, USA) stained with ethidium bromide
and visualized by UV light. The identity of the ampli¢ed PCR product
was con¢rmed by its direct sequencing (Sequencing unit, Biological
services, The Weizmann Institute of Science, Israel).
3. Results
3.1. Proliferative e¡ects of VIP, PACAP27 and SNV
In the present study, we aimed at comparing the prolifer-
ative e¡ect of VIP and its closely related peptide, PACAP27,
on human keratinocytes. Fig. 1A shows that VIP (maximal
e¡ect 2.5-fold), and to a lesser extent PACAP27 (maximal
e¡ect 1.5-fold), served as mediators of proliferation of pri-
mary neonatal keratinocytes. Proliferative e¡ects were de-
Table 1
Primer sequence and expected ampli¢ed band size for VIP, PACAP, PAC1, VPAC1, VPAC2 receptors and GAPDH
Name Sense Antisense Size
VIP (nucleotide 419) 5P-TCACTGACAACTATACCCGCC-3P (nucleotide 809) 5P-ACAGCATATGAAATTGCAGGC-3P 390
PACAP (nucleotide 11 664) 5P-GATCTTCACGGACAGCTACAG-3P (nucleotide 11 889) 5P-GTTTGGATAGAACACACGAGC-3P 225
VPAC1R (nucleotide 1 706) 5P-CCCCCTGCTGGGTCTTCTGC-3P (nucleotide 2 110) 5P-ATTCGCTGGTGGCTGCCTTCTCAT-3P 405
VPAC2R (nucleotide 372) 5P-CTGCACGGTGCCCTGCCCAAAAGT-3P (nucleotide 835) 5P-GCCCCTCCACCAGCAGCCAGAAGA-3P 464
PAC1R (nucleotide 458) 5P-ATGGTCCTGGTCAGCTGCCCTGAGCTC-3P (nucleotide 674) 5P-CAGTCTCAGATTCATATTCATC-3P 217
PAC1R (nucleotide 1 200) 5P-TTAACTTTGTGCTTTTTATTGGC-3P (nucleotide 1 383) 5P-TCCCTTTTGCTGACATTC-3P 183
GAPDH (nucleotide 371) 5P-CCATGGAGAAGGCTGGGG-3P (nucleotide 570) 5P-CAAAGTTGTCATGGATGACC-3P 200
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scribed before for VIP on human keratinocytes (7^9). PA-
CAP27 has never been evaluated with respect to keratinocytes
before but, not surprisingly, its activity pro¢le was similar to
that of VIP, exhibiting optimal active concentrations at nM
and below. Further evaluation of VIP and PACAP27 e¡ects
on the keratinocytic cell line, HaCaT [16], following starva-
tion, are depicted in Fig. 1B. The optimal activity of VIP was
evident at 10311 M. E¡ects were relatively small (40% in-
crease) and were rather similar for both VIP and PACAP.
Evidently, both VIP and PACAP27 were more e⁄cacious in
the neonatal keratinocytes, as compared to the HaCaT cell
line (Fig. 1A,B).
As the results with VIP indicated an association with high
a⁄nity VIP receptors, the high a⁄nity VIP receptor preferring
analog, SNV, was tested. SNV displayed potent mitogenic
activity (EC50 of V33 fM) and was up to two-fold more
e⁄cacious as compared to VIP and PACAP27 (Fig. 1B).
3.2. RT-PCR: VIP/PACAP receptor expression
RT-PCR (30^35 cycles) was utilized for speci¢c mRNA
determination in HaCaT cells and in keratinocytes of primary
human origin. Under normal culture conditions, the presence
of the two known and cloned VPAC receptors, VPAC1 and
VPAC2, was revealed. However, the cells lacked the speci¢c
PAC1 receptor type (Fig. 2), regardless of the di¡erent known
splice variants (as primers were designed to recognize the N-
terminal extracellular domain of the receptor protein, shared
by all the PACAP receptor variants). Further evaluation of
the PAC1R by alternative primers, aimed at amplifying a se-
quence within the junction associating the seventh transmem-
brane domain and C-terminal intracellular domain, also failed
to yield an ampli¢ed product. The human neuroblastoma cell
line, NMB, served as a positive control (in which the presence
of PAC1R has not been previously shown). No product was
evident in identical PCRs performed in parallel without RNA.
Results presented thus indicate that any e¡ect of PACAP is
likely to be mediated through the receptors shared by VIP and
PACAP, the VPAC receptors 1 and/or 2.
3.3. VIP and PACAP: autocrine or paracrine e¡ectors in
keratinocytes?
As evidenced from RT-PCR results (Fig. 2), keratinocytes
did not express VIP mRNA, even when the PCR was ex-
tended to 35 cycles. These results imply that VIP does not
operate in an autocrine fashion in keratinocytes. Surprisingly,
keratinocytes did express low quantities of PACAP mRNA.
Lower quantities of this peptide were expressed in 3‡ kerati-
nocytes compared to the HaCaT line (Fig. 2). As a positive
control for VIP mRNA expression, the non-small-cell-lung
carcinoid, NCI-H727, was used [18].
3.4. E¡ects of starvation
Since the proliferative activity of VIP was demonstrated in
starved HaCaT cells, we turned to examine whether the star-
Fig. 1. E¡ects of VIP and PACAP27 on [3H]thymidine incorpora-
tion into 4‡ human keratinocytes (A) and VIP, PACAP27 and SNV
on human HaCaT cell line (B). A: Human neonatal keratinocytes
were seeded, 150 000/35 mm dishes in BPE- and EGF-supplemented
K-SFM and grown until 50% con£uency. Following 48 h in basal
medium, VIP/PACAP27 at the indicated concentrations were added
in fresh basal medium for an additional 22^24 h. The e¡ects of the
peptides were monitored by [3H]thymidine incorporation (4 WCi/
dish) during the last 4 h of incubation. Mean þ S.E.M. of two (VIP,
open bar) or three (PACAP27, hatched bar) independent experi-
ments are indicated. *P6 0.05; **P6 0.005; ***P6 0.0005 by Stu-
dent’s t-test. Control cultures yielded V5000 cpm. B: HaCaT cells
were seeded, 4U105/35 mm dish, in 5% FCS-supplemented MEM.
The following day, cells were starved by changing the medium to
MEM supplemented with 0.1% BSA for a 48 h period, after which
the peptides were added, in fresh medium, at the speci¢ed concen-
trations and incubation proceeded for 22^24 h period. The e¡ects of
the peptides were monitored by [3H]thymidine incorporation during
the last 4 h of incubation. Mean þ S.E.M. of four independent ex-
periments for each peptide are indicated. VIP, open bar, SNV,
hatched leftward, PACAP27 closed bar. *P6 0.05; **P6 0.005;
***P6 0.0005 by Student’s t-test. Control cultures yielded V50 000
cpm.
Fig. 2. RT-PCR results with primers for VPAC1, VPAC2, PAC1 re-
ceptors, VIP, PACAP27 and GAPDH, on HaCaT, starved HaCaT
and 3‡ human keratinocytes. Complementary DNA was obtained
and ampli¢ed from mRNA, isolated from HaCaT line cultured
under normal conditions (10% FCS supplemented medium), starved
HaCaT (cultured in 0.1% BSA supplemented medium for 48 h) and
3‡ human keratinocytes (cultured in complete K-SFM) with the in-
dicated primers. Results depicted are from one experiment, represen-
tative of three others. In the absence of an ampli¢ed product, NCI-
H727 (RT-PCR for VIP) and the human neuroblastoma cell line,
NMB (RT-PCR for PAC1R) served as positive controls.
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vation protocol was accompanied by changes in receptor ex-
pression by the cells. Thus, a qualitative and indicative ap-
proach, using GAPDH as an internal standard, was adopted
to assess receptor mRNA expression in non-starved versus
starved HaCaT cells. The results obtained are presented in
Fig. 2. The starvation procedure indicated an apparent dou-
bling of VPAC1R expression and no parallel change in the
VPAC2R. In addition, starvation did not seem to in£uence
the level of expression of the PACAP mRNA, or the unde-
tected expression of VIP mRNA.
It is of interest to note that while cells survived relatively
well the starvation protocol they have undergone a profound
morphological change (as shown in the adjoining manuscript).
Instead of the normal ‘cobblestone’ arrangement of the cells,
the cells became elongated, with de¢ned spaces and bounda-
ries between them. This change was only partly reversible,
when the cells were switched back to serum (10%) containing
medium (not shown).
3.5. Cyclic nucleotides and NO
Since both VPAC1 and VPAC2 receptors are members of
the G-protein coupled receptors, associated with adenylate
cyclase activation, intracellular cAMP levels were evaluated.
As can be seen in Fig. 3A, while incubation HaCaT cells with
VIP resulted in dose-dependent increases in cAMP (EC50 of
V1 nM), incubation with SNV did not alter cAMP produc-
tion. In contrast, both VIP and SNV activated cGMP forma-
tion dose-dependently, with two peaks of activity, as well as a
similar maximal e¡ect (Fig. 3B). A peak for cGMP produc-
tion was observed at 10312 M for SNV and at 10311 M for
VIP, corresponding to the concentrations providing maximal
cell proliferation e¡ects.
Since guanylate cyclase might be activated via two di¡erent
pathways, either direct receptor stimulation (particulate GC)
[19] or via NO activation of the soluble GC [20], the possi-
bility of NO-dependent activation was explored. Thus, se-
creted NO levels, of cultures exposed to VIP or SNV, were
quanti¢ed by the NO32 metabolite, using the Griess reaction.
Dose-dependent elevations in NO32 were detected with VIP,
with a sustained e¡ect, of 140^160%, at the 10314^10311 M
concentration range, with a highly signi¢cant peak at 10312 M
(Fig. 4). A more e⁄cacious e¡ect was obtained with SNV,
that more than doubled NO32 levels. The active VIP/SNV
concentrations corresponded well to those required for opti-
mal cGMP induction and optimal mitogenic e¡ects.
4. Discussion
The current report shows that nanomolar concentrations of
VIP induce primary keratinocyte proliferation. Further results
indicated that PACAP27 (to a lesser extent) and SNV (to a
higher extent) mimicked VIP-associated keratinocyte prolifer-
ative activity. PACAP mRNA was detected in the human
keratinocyte, suggesting PACAP as an autocrine growth fac-
tor. In contrast, VIP mRNA was not detected in keratino-
cytes, suggesting a paracrine activity.
A less e⁄cacious mitogenic e¡ect of the peptides on HaCaT
cells was discovered and can be explained by HaCaT being an
immortalized, rapidly multiplying cell line, independent of
Fig. 3. E¡ects of VIP and SNV on intracellular cAMP (A) and
cGMP (B) production by starved HaCaT cells. HaCaT cells were
seeded as for proliferation assay. Cyclic AMP/cGMP levels were de-
termined following 15 min incubation with VIP (closed circle) or
SNV (open circle), at the indicated concentrations, using EIA.
Mean þ S.E.M. of two independent experiments are indicated. A:
Control cultures yielded V900 fmol/dish cAMP. *P6 0.0005;
**P6 0.0000005; by Student’s t-test. B: Control cultures yielded
V150 fmol/dish cGMP. *P6 0.05; **P6 0.01, ***P6 0.003 by
Student’s t-test.
Fig. 4. E¡ects of VIP and SNV on the secreted NO levels by
starved HaCaT cultures. HaCaT cells were seeded as for prolifera-
tion (see Fig. 1). NO was determined following 24 h incubation
with the indicated concentrations of VIP (open bar) or SNV
(hatched bar), by the Griess reaction for the NO32 metabolite.
Mean þ S.E.M. of three independent experiments are indicated. Con-
trol cultures yielded V4 WM NO32 . *P6 0.05; **P6 0.0006;
***P6 0.00005 by Student’s t-test.
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strict growth control regulation. In order for HaCaT cells to
respond to VIP, a serum starvation protocol was required. In
previous studies, VIP’s proliferative activity on HaCaT cells
was dependent on serum, or rather the lack of it, in the tested
culture, with a 50% increase at 10311 M VIP in serum-free
cultures. No proliferative e¡ect of VIP was evident when cells
were cultured in 10% FCS supplemented medium [21].
Our results now indicate increased expression of VPAC1R
in HaCaT cells maintained in serum-free conditions, with un-
changed expression of VPAC2R upon starvation and no de-
tectable expression of PAC1. Thus, the VPAC1R is suggested
to be associated with the VIP/PACAP proliferative e¡ects.
Other expression studies have suggested that in skin biopsies,
PAC1R can be identi¢ed. However, the cellular location is still
to be resolved [22].
VIP was previously demonstrated to act as a survival factor
for cultured neurons [23]. Thus, the apparent up-regulation of
VIP receptors in serum-starved keratinocytes, may indicate
that VIP functions as a survival factor for these cells. Like
our results, serum deprivation has been shown before to mod-
ulate VIP binding sites in melanoma cells [24]. Since VPAC2R
expression in starved HaCaT did not show a parallel change,
the suggested over-expression of VPAC1R receptor induced
by serum starvation is a speci¢c rather than a generalized
event. As was already suggested, in the HaCaT cells, the ele-
vation of VPAC1R, or the change in the ratio between the
VPAC1 and the VPAC2 receptor expression, is correlated with
increased proliferation, or at least increased responsiveness, to
VIP or its related peptides. NCI-H727 is known to express
high VIP receptor levels [25] and we have observed that only
VPAC1, and not VPAC2 receptor type, is expressed in these
cells (not shown). The line was also highly responsive to VIP
and a starvation protocol was not required in order to obtain
profound proliferative e¡ects of both VIP and SNV (not
shown). Indirectly, these results support the importance of
high VPAC1R levels, in mediating proliferation. Furthermore,
the lack of VPAC2R as a potential interfering signal may
account for the non-requirement for serum deprivation for
VIP stimulation of NCI-H727 cells division. Similarly, Jiang
et al. [26] implicated the VPAC1R in VIP (10310M) induced
growth of Capan-2 (human pancreatic adenocarcinoma cell
line), as the cells lack the VPAC2R entirely. On the other
hand, Zupan et al. [27] have suggested that VIP induced as-
trocytogenesis is mediated by the VPAC2R. Thus, similar ef-
fects may be mediated by di¡erent receptors, depending on
the cell type. Taken together, the receptors’ expression is
tightly regulated, allowing VIP/PACAP to stimulate/inhibit
cell proliferation/di¡erentiation [1].
Evaluation of the lipophilic VIP analog, SNV, in the Ha-
CaT system, resulted in a marked mitogenic e¡ect: almost
double [3H]thymidine incorporation at 10312 M SNV. The
low (pM and lower) and broad range of active concentrations
(pM^nM) of SNV paralleled results in other systems, e.g.
neuroprotection [13,14]. The superiority of SNV, as mani-
fested in the HaCaT proliferation assay, combined with the
increased stability and membranal penetration capacity of the
peptide [12], may thus enable its development as a therapeutic
agent for the treatment of compromised skin conditions, re-
quiring enhancement of the proliferative rate of keratinocytes.
The setting for VIP to act as a physiological, locally re-
leased growth stimulatory factor in wound healing is further
supported by several aspects. These include the demonstration
of VIP-like-immunoreactivity (VIP-LI) nerve ¢bers in close
proximity to hair follicles, sweat gland ducts and the basal
cell layer of the epidermis [28], structures from which epithe-
lialization is initiated. Sensory nerve ¢bers have been shown
to sprout during wound healing, resulting in hyperinnerva-
tion, which is normalized after healing [29]. Furthermore,
VIP was demonstrated to dramatically induce HaCaT cell
migration and colonization on polyurethane matrix as well
as ‘wound’ closure, after a ‘wound’ was made by scratching
con£uent cultures with a razor blade [30]. Because of the
similarity between VIP and PACAP27, the shared functions
and receptors, PACAP as well may be regarded as an impor-
tant contributor in wound healing, especially since our results
indicated that it may also operate in an autocrine fashion. As
in other situations, the biological e¡ect of a single agent may
arise not so much from its sole activity, but may be modulated
(enhanced or diminished) by the presence of other agents.
This phenomenon was previously demonstrated by the syner-
gism in the e¡ect of VIP and leukotriene B4 on keratinocytes
proliferation [9]. In contrast, co-incubation of VIP and sub-
stance P resulted in an antagonistic e¡ect, not only blocking
VIP mitogenicity, but yielding cell counts even lower than in
the control [8]. Thus, an intricate balance between similar and
competing signals exists, which may exert a tonic control over
normal basal cell layer division, as well as the abnormal one
(e.g. psoriasis and other in£ammatory skin conditions).
While VIP dose-dependently activated cAMP accumula-
tion, SNV was not associated with this second messenger.
In addition, the VIP concentrations required for inducing
cAMP, did not correlate with the concentrations required
for a proliferative e¡ect. Similar results were previously dem-
onstrated in astrocytes [13], suggestive of a common pathway.
Furthermore, previous studies have associated the prolifera-
tive e¡ect of VIP on keratinocytes with cAMP elevation [7],
the results presented here, regarding VIP’s and SNV’s e¡ect
on HaCaT cells, do not support this notion. However, the
culture conditions and cellular origin di¡er, as well as the
active VIP concentrations (nM here and WM in the previous
studies).
Neither VPAC1 nor VPAC2 receptors were previously re-
ported to be associated in any form with cGMP induction.
Nor was the proliferative e¡ect of VIP on keratinocytes asso-
ciated with this second messenger. Furthermore, VIP, and to a
higher degree, SNV, stimulated NO secretion dose-depend-
ently. The active VIP/SNV concentrations corresponded well
to those required for optimal cGMP induction and optimal
mitogenic e¡ects. Hence, NO/cGMP are likely to constitute
part of the messenger loop responsible for the VIP-mitogenic
e¡ect.
The e¡ects of NO on keratinocytes are of some contro-
versy: studies, supporting both NO as a growth arrest factor
and a di¡erentiation inducer in keratinocytes as well as pro-
proliferation agent were published. A recent study [31] has
tried to reconcile the controversy, suggesting a dose-depen-
dent e¡ect of NO: using chemical NO generating agents,
such as SNAP, they have demonstrated a biphasic e¡ect of
NO, with low concentration (6 0.5 mM) inducing prolifera-
tion, and higher concentrations (s 1 mM) inducing di¡eren-
tiation. The present results, described for VIP and SNV, seem
to support a proliferative e¡ect of NO, either by itself, and/or
mediated by increased cGMP. Furthermore, SNV is ten-fold
more potent than VIP in inducing cGMP, and a more e⁄ca-
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cious inducer of NO, which may explain its higher mitogenic
e¡ect in HaCaT cells. To the best of our knowledge, this is the
¢rst time that a peptide, VIP, is shown to elevate NO in
keratinocytes. The observed potency of VIP-induced cGMP
in keratinocytes is paralleled only in mixed cultures of rat
cortical astrocytes^neurons, where 10311 M VIP induced
V1.7-fold increase in cGMP [32].
Taken together, the results presented here indicate a possi-
ble role for VIP and PACAP27 as mitogens to keratinocytes,
operating via speci¢c membranal receptors and second mes-
sengers. The proliferative e¡ect is a direct one, as our in vitro
system is devoid of other cell types. Furthermore, from a
clinical point of view, this study has identi¢ed a superior
proliferation inducer, SNV, which may enable arti¢cial ma-
nipulation of keratinocytes’ growth, in a manner that may
serve in pathological skin conditions.
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